|Bid||72.96 x 0|
|Ask||73.54 x 0|
|Day's Range||73.51 - 73.51|
|52 Week Range||55.42 - 81.61|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||24.60|
|Forward Dividend & Yield||0.81 (1.11%)|
|1y Target Est||N/A|
Oakmark Funds released its 2019 Q3 letter to investors giving its commentary on a number of its positions, highlighting the investment strategy and stock picks for the quarter- download a copy here. The investment management company did not have a good quarter, losing 2.1%, while the S&P 500 gained 1.7%. For the fiscal year ending September 30, […]
So much for the October Effect.Stocks have a reputation for declining in October, and no wonder: Some of the market's darkest days, including 1929's Black Tuesday/Thursday and 1987's Black Monday--occurred during that month.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Baxter stock plunged to a four-month low in heavy volume Thursday after the medical technology firm announced an accounting investigation that overshadowed a relatively strong third quarter.
Medical products company Baxter International Inc. said Thursday it has launched an investigation of misstatements in previously reported non-operating income related to foreign exchange gains and losses. Deerfield, Ill.-based Baxter said the investigation involves intra-company transactions undertaken for the purpose of generating forex gains and losses, that used a forex rate convention that did not comply with Generally Accepted Accounting Principles, or GAAP, the U.S. accounting standard. The result was certain misstatements in numbers reported in the period stretching from 2014 through the first half of 2019. The company's audit committee is overseeing the probe with the help of independent external advisers. The company has voluntarily disclosed the probe to the Securities and Exchange Commission. It does not expect to file its 10-Q for the September quarter in a timely manner. The Company is taking steps to strengthen and enhance its internal controls, and we look forward to sharing our full financial results as soon as possible," Chief Executive José Almeida said in a statement. The company is expecting third-quarter revenue to rise 3% to $2.85 billion and expects fourth-quarter sales to grow 3% to 4%. Shares fell about 7% in premarket trade, but have gained 34% in 2019, while the S&P 500 has gained 20%.
Medical supply company Baxter International Inc has been named in a complaint along with other makers and distributors of opioids for improperly marketing the drugs, a filing showed on Thursday. Baxter, which also makes generic drugs, said it was served in August with the amended complaint filed by Fayette County in the multi-district litigation pending in U.S. District Court, Northern District of Ohio. The drugmaker said it made injectable generic opioid drugs in its facility in New Jersey which was divested in 2011.
Preliminary third-quarter sales numbers miss analysts' forecasts. The medical-products company is also investigating misstatements in previously reported non-operating income.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
Baxter manufacturers medically necessary products and the company enjoys a high market share across multiple health care segments, Mishan wrote in the note. The company deserves credit for recent new product launches and geographic expansions but these aren't notable enough to exceed management's 5% to 6% organic growth through 2023.
On a per-share basis, the Deerfield, Illinois-based company said it had net income of 66 cents. Earnings, adjusted for non-recurring costs, came to 76 cents per share. The results beat Wall Street expectations. ...